Lpath announces that its multicenter, Phase 2 Nexus clinical trial evaluating iSONEP in patients with wet age-related macular degeneration did not meet its primary or key secondary endpoints (shares halted) (LPTN) : Wet AMD patients who had not responded adequately to existing anti-vascular endothelial growth factor therapies including Lucentis, Avastin and Eylea did not show any statistically significant improvement in visual acuity when treated with iSONEP as an adjunctive or monotherapy. Full study results will be presented during the Retina Subspecialty Days in conjunction with the American Academy of Ophthalmology in Las Vegas, Nevada in November 2015. In addition to iSONEP, Lpath has three drug candidates in its pipeline
Who could it be?? My money is on Valeant.
Aldeyra Therapeutics announces first patient enrolled in noninfectious anterior Uveitis Phase II clinical trial (ALDX) : Co announced that it has enrolled the first patient in its Phase II clinical trial of NS2 for the treatment of noninfectious anterior uveitis. The study is being conducted at top U.S. anterior uveitis clinical trial sites, and led by Dr. Stephen Foster, a recognized clinical expert in ocular inflammation.